High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects

Journal of Allergy and Clinical Immunology

Volumn 132, Issue 2, 2013, Pages

  Busse, William ^a   Spector, Sheldon ^b   Rosén, Karin ^c   Wang, Yan ^c   Alpan, Oral ^d  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GENENTECH INC   (United States)

^d O and O Alpan   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; IMMUNOGLOBULIN E; OMALIZUMAB; PLACEBO;

ADULT; AGED; ASTHMA; CHILD; DISEASE EXACERBATION; EOSINOPHIL COUNT; HUMAN; LETTER; PRIORITY JOURNAL; SCHOOL CHILD;

EID: 84881172210     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2013.02.032     Document Type: Article

References (16)

1. P.M. O'Byrne, P.J. Barnes, R. Rodriguez-Roisin, E. Runnerstrom, T. Sandstrom, and K. Svensson Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial Am J Respir Crit Care Med 164 2001 1392 1397
2. L.J. Walsh, C.A. Wong, S. Cooper, A.R. Guhan, M. Pringle, and A.E. Tattersfield Morbidity from asthma in relation to regular treatment: a community based study Thorax 54 1999 296 300
3. D. Price The use of omalizumab in asthma Prim Care Respir J 17 2008 62 72
4. K.F. Chung Anti-IgE monoclonal antibody, omalizumab: a new treatment for allergic asthma Expert Opin Pharmacother 5 2004 439 446
5. R.L. Shields, W.R. Whether, K. Zioncheck, L. O'Connell, B. Fendly, and L.G. Presta Inhibition of allergic reactions with antibodies to IgE Int Arch Allergy Immunol 107 1995 308 312
6. ®) label. Novartis US, Genentech, January 2010. Available at: http://www.gene.com. Accessed December 4, 2012.
7. A. Fuhlbrigge, D. Peden, A.J. Apter, H.A. Boushey, C.A. Camargo Jr., and J. Gern Asthma outcomes: exacerbations J Allergy Clin Immunol 129 2012 S34 S48
8. C. Prussin, and D.D. Metcalfe 4. IgE, mast cells, basophils, and eosinophils J Allergy Clin Immunol 111 2003 S486 S494
9. M. Massanari, S.T. Holgate, W.W. Busse, P. Jimenez, F. Kianifard, and R. Zeldin Effect of omalizumab on peripheral blood eosinophilia in allergic asthma Respir Med 104 2010 188 196
10. S.J. Szefler, S. Wenzel, R. Brown, S.C. Erzurum, J.V. Fahy, and R.G. Hamilton Asthma outcomes: biomarkers J Allergy Clin Immunol 129 2012 S9 23
11. A. Fuhlbrigge, D. Peden, A.J. Apter, H.A. Boushey, C.A. Camargo, and J. Gern Asthma outcomes: exacerbations J Allergy Clin Immunol 129 2012 S1 S8
12. American Thoracic Society Standardization of spirometry, 1994 update Am J Respir Crit Care Med 152 1995 1107 1136
13. R.O. Crapo, A.H. Morris, and R.M. Gardner Reference spirometric values using techniques and equipment that meet ATS recommendations Am Rev Respir Dis 123 1981 659 664
14. G. Polgar, and V. Promadhat Pulmonary function testing in children: techniques and standards 1971 WB Saunders Philadelphia
15. Global Initiative for Asthma. The global strategy for asthma management and prevention. 2012. Available at: http://www.ginasthma.org/. Accessed December 4, 2012.
16. H. Reddel, D.R. Taylor, E.D. Bateman, L.P. Boulet, H.A. Boushey, and W.W. Busse An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations Standardizing Endpoints for Clinical Asthma Trials and Clinical Practice Am J Respir Crit Care Med 180 2009 59 99